These results suggest that the combination of cetuximab with an Akt1/2/3 inhibitor might be a potential novel therapeutic combination strategy to overcome acquired cetuximab resistance in HNSCC cell lines. The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.